Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


Articles published in Ann Surg

Retrieve available abstracts of 113 articles:
HTML format



Single Articles


    December 2022
  1. CARBONI F, Valle M
    Comment on: "Gastrectomy Versus Esophagectomy For Gastroesophageal Junction Tumors: Short-And Long-term Outcomes From the Dutch Upper GI Cancer Audit".
    Ann Surg. 2022;276:e1121.
    PubMed    


  2. GOTTLIEB-VEDI E, Kauppila JH, Mattsson F, Lindblad M, et al
    Long-term Survival in Esophageal Cancer After Minimally Invasive Esophagectomy Compared to Open Esophagectomy.
    Ann Surg. 2022;276:e744-e748.
    PubMed     Abstract available


  3. KALFF MC, Fransen LFC, de Groot EM, Gisbertz SS, et al
    Long-term Survival After Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Propensity-score Matched Analysis.
    Ann Surg. 2022;276:e749-e757.
    PubMed     Abstract available


  4. SIHAG S, Nobel T, Hsu M, De La Torre S, et al
    Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?
    Ann Surg. 2022;276:1017-1022.
    PubMed     Abstract available


  5. JEZERSKYTE E, Mertens AC, Dieren SV, Eshuis WJ, et al
    Gastrectomy Versus Esophagectomy for Gastroesophageal Junction Tumors: Short- and Long-Term Outcomes From the Dutch Upper Gastrointestinal Cancer Audit.
    Ann Surg. 2022;276:e735-e743.
    PubMed     Abstract available


    November 2022
  6. DONLON NE, Moran B, Kamilli A, Davern M, et al
    CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison.
    Ann Surg. 2022;276:792-798.
    PubMed     Abstract available


  7. PERA M, Gibert J, Gimeno M, Garsot E, et al
    Machine Learning Risk Prediction Model of 90-day Mortality After Gastrectomy for Cancer.
    Ann Surg. 2022;276:776-783.
    PubMed     Abstract available


  8. COOLS-LARTIGUE J, Markar S, Mueller C, Hofstetter W, et al
    An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma.
    Ann Surg. 2022;276:799-805.
    PubMed     Abstract available


  9. WANG S, Huang S, Gao Z, Zhuang W, et al
    Comment on: The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-Negative Esophageal Adenocarcinoma.
    Ann Surg. 2022;276:e645.
    PubMed    


  10. OKAMURA A, Yamamoto H, Watanabe M, Miyata H, et al
    Association Between Preoperative HbA1c Levels and Complications after Esophagectomy: Analysis of 15,801 Esophagectomies From the National Clinical Database in Japan.
    Ann Surg. 2022;276:e393-e399.
    PubMed     Abstract available


  11. RAFTERY NB, Murphy CF, Donohoe CL, O'Connell B, et al
    The Complexity of Defining Postoperative Pneumonia After Esophageal Cancer Surgery: A Spectrum of Lung Injury Rather Than a Simple Infective Complication?
    Ann Surg. 2022;276:e400-e406.
    PubMed     Abstract available


  12. KINGMA BF, Grimminger PP, van der Sluis PC, van Det MJ, et al
    Worldwide Techniques and Outcomes in Robot-assisted Minimally Invasive Esophagectomy (RAMIE): Results From the Multicenter International Registry.
    Ann Surg. 2022;276:e386-e392.
    PubMed     Abstract available


    October 2022
  13. KANDIL E, Omar M, Aboueisha M, Attia AS, et al
    Efficacy and Safety of Radiofrequency Ablation of Thyroid Nodules: A Multi-institutional Prospective Cohort Study.
    Ann Surg. 2022;276:589-596.
    PubMed     Abstract available


    August 2022
  14. RHODIN KE, Raman V, Jensen CW, Kang L, et al
    The Effect of Center Esophagectomy Volume on Outcomes in Clinical Stage I-III Esophageal Cancer.
    Ann Surg. 2022 Aug 30. pii: 00000658-990000000-00247.
    PubMed     Abstract available


  15. RAJA S, Rice TW, Lu M, Semple ME, et al
    Adjuvant Therapy after Neoadjuvant Therapy for Esophageal Cancer: Who Needs It?
    Ann Surg. 2022 Aug 23. pii: 00000658-990000000-00237.
    PubMed     Abstract available


  16. CHANDRA R, Reznik SI
    Vacutainers and Primers Over X-Rays and Gamma Rays: The Role of Circulating Tumor DNA in Esophageal Adenocarcinoma Staging and Surveillance: Invited Commentary on "Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Aden
    Ann Surg. 2022;276:e127-e128.
    PubMed    


  17. CABALAG CS, Yates M, Corrales MB, Yeh P, et al
    Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
    Ann Surg. 2022;276:e120-e126.
    PubMed     Abstract available


  18. SIHAG S, Nobel T, Hsu M, Tan KS, et al
    A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma.
    Ann Surg. 2022;276:312-317.
    PubMed     Abstract available


  19. YANES M, Santoni G, Maret-Ouda J, Ness-Jensen E, et al
    Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries.
    Ann Surg. 2022;276:e79-e85.
    PubMed     Abstract available


    July 2022
  20. KALFF MC, Henckens SPG, Voeten DM, Heineman DJ, et al
    Recurrent Disease after Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study.
    Ann Surg. 2022 Jul 26. pii: 00000658-990000000-00187.
    PubMed     Abstract available


  21. WONG IYH, Chung JCY, Zhang RQ, Gao X, et al
    A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) with Lymph Node Status (ypN-category) Results in Better Prognostication than ypTNM Stage Groups after Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
    Ann Surg. 2022 Jul 25. pii: 00000658-990000000-00184.
    PubMed     Abstract available


  22. MATSUDA S, Kitagawa Y, Takemura R, Okui J, et al
    Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
    Ann Surg. 2022 Jul 15. pii: 00000658-990000000-00138.
    PubMed     Abstract available


  23. HIRANO Y, Konishi T, Kaneko H, Itoh H, et al
    Impact of Prophylactic Corticosteroid Use on In-hospital Mortality and Respiratory Failure after Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan.
    Ann Surg. 2022 Jul 14. pii: 00000658-990000000-00106.
    PubMed     Abstract available


  24. JUNTTILA A, Helminen O, Helmio M, Huhta H, et al
    Five-year Survival after McKeown Compared to Ivor-Lewis Esophagectomy for Esophageal Cancer: A Population-based Nationwide Study in Finland.
    Ann Surg. 2022 Jul 12. pii: 00000658-990000000-00103.
    PubMed     Abstract available


  25. ZHANG Y, Cao Y, Zhang J, Huang M, et al
    Lymph Node Ratio Improves Prediction of Overall Survival in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy: A National Cancer Database Analysis.
    Ann Surg. 2022 Jul 6. pii: 00000658-990000000-00063.
    PubMed     Abstract available


  26. JOGIAT UM, Sasewich H, Turner SR, Baracos V, et al
    Sarcopenia Determined by Skeletal Muscle Index Predicts Overall Survival, Disease-free Survival, and Postoperative Complications in Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
    Ann Surg. 2022 Jul 6. pii: 00000658-990000000-00081.
    PubMed     Abstract available


  27. HOSOI T, Abe T, Higaki E, Fujieda H, et al
    Circular Stapled Technique Versus Modified Collard Technique for Cervical Esophagogastric Anastomosis After Esophagectomy: A Randomized Controlled Trial.
    Ann Surg. 2022;276:30-37.
    PubMed     Abstract available


  28. MOTOYAMA S, Maeda E, Iijima K, Sato Y, et al
    Does Esophagectomy Provide a Survival Advantage to Patients Aged 80 Years or Older? Analyzing 5066 Patients in the National Database of Hospital-based Cancer Registries in Japan.
    Ann Surg. 2022;276:e16-e23.
    PubMed     Abstract available


  29. POINTER DT JR, Saeed S, Naffouje SA, Mehta R, et al
    Outcomes of 350 Robotic-assisted Esophagectomies at a High-volume Cancer Center: A Contemporary Propensity-score Matched Analysis.
    Ann Surg. 2022;276:111-118.
    PubMed     Abstract available


  30. HUGHES DT, Reyes-Gastelum D, Ward KC, Hamilton AS, et al
    Barriers to the Use of Active Surveillance for Thyroid Cancer Results of a Physician Survey.
    Ann Surg. 2022;276:e40-e47.
    PubMed     Abstract available


    May 2022
  31. OKUNO K, Tokunaga M, Kinugasa Y, Baba H, et al
    A Transcriptomic Liquid Biopsy Assay for Predicting Resistance to Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma.
    Ann Surg. 2022 May 13. pii: 00000658-990000000-00001.
    PubMed     Abstract available


  32. CLAASSEN L, Hannink G, Luyer MDP, Ainsworth AP, et al
    Learning Curves of Ivor Lewis Totally Minimally Invasive Esophagectomy by Hospital and Surgeon Characteristics: A Retrospective Multinational Cohort Study.
    Ann Surg. 2022;275:911-918.
    PubMed     Abstract available


  33. FRANSEN LFC, Janssen THJB, Aarnoudse M, Nieuwenhuijzen GAP, et al
    Direct Oral Feeding After a Minimally Invasive Esophagectomy: A Single-Center Prospective Cohort Study.
    Ann Surg. 2022;275:919-923.
    PubMed     Abstract available


    April 2022
  34. SHEN Y, Zhang Y, He M, Fang Y, et al
    Advancing Gastroscope From Intraluminal to Extraluminal Dissection: Primary Experience of Laparo-gastroscopic Esophagectomy.
    Ann Surg. 2022;275:e659-e663.
    PubMed     Abstract available


  35. SUH YS, Na D, Lee JS, Chae J, et al
    Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas.
    Ann Surg. 2022;275:706-717.
    PubMed     Abstract available


  36. KAMARAJAH SK, Phillips AW, Hanna GB, Low DE, et al
    Is Local Endoscopic Resection a Viable Therapeutic Option for Early Clinical Stage T1a and T1b Esophageal Adenocarcinoma?: A Propensity-matched Analysis.
    Ann Surg. 2022;275:700-705.
    PubMed     Abstract available


    March 2022
  37. KUPPUSAMY MK, Low DE
    Evaluation of International Contemporary Operative Outcomes and Management Trends Associated With Esophagectomy: A 4-Year Study of >6000 Patients Using ECCG Definitions and the Online Esodata Database.
    Ann Surg. 2022;275:515-525.
    PubMed     Abstract available


  38. RAMAN V, Jawitz OK, Farrow NE, Voigt SL, et al
    The Relationship Between Lymph Node Ratio and Survival Benefit With Adjuvant Chemotherapy in Node-positive Esophageal Adenocarcinoma.
    Ann Surg. 2022;275:e562-e567.
    PubMed     Abstract available


    February 2022
  39. LI S, Ai Q, Liang H, Liu H, et al
    Nonintubated Robotic-assisted Thoracic Surgery for Tracheal/Airway Resection and Reconstruction: Technique Description and Preliminary Results.
    Ann Surg. 2022;275:e534-e536.
    PubMed     Abstract available


  40. MARKAR SR, Zaninotto G, Castoro C, Johar A, et al
    Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study.
    Ann Surg. 2022;275:e392-e400.
    PubMed     Abstract available


  41. RUCKER AJ, Raman V, Jawitz OK, Voigt SL, et al
    The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma.
    Ann Surg. 2022;275:348-355.
    PubMed     Abstract available


    January 2022
  42. ELLIOTT JA, Markar SR, Klevebro F, Johar A, et al
    An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE).
    Ann Surg. 2022 Jan 27. pii: 00000658-900000000-93088.
    PubMed     Abstract available


  43. SANABRIA A, Betancourt C, Sanchez JG, Garcia C, et al
    Prophylactic Central Neck Lymph Node Dissection in Low-Risk Thyroid Carcinoma Patients Does not Decrease the Incidence of Locoregional Recurrence: A Meta-Analysis of Randomized Trials.
    Ann Surg. 2022 Jan 24. pii: 00000658-900000000-93112.
    PubMed     Abstract available


  44. BOSHIER PR, Klevebro F, Savva KV, Waller A, et al
    Assessment of Health Related Quality of Life and Digestive Symptoms in Long-term, Disease Free Survivors After Esophagectomy.
    Ann Surg. 2022;275:e140-e147.
    PubMed     Abstract available


  45. HARRIS A, Butterworth J, Boshier PR, MacKenzie H, et al
    Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials.
    Ann Surg. 2022;275:121-130.
    PubMed     Abstract available


    December 2021
  46. OSHIKIRI T, Numasaki H, Oguma J, Toh Y, et al
    Prognosis of Patients with Esophageal Carcinoma following Routine Thoracic Duct Resection: A Propensity-matched Analysis of 12,237 Patients based on the Comprehensive Registry of Esophageal Cancer in Japan.
    Ann Surg. 2021 Dec 14. pii: 00000658-900000000-93155.
    PubMed     Abstract available


  47. CLAASSEN L, Hannink G, van Workum F, Rosman C, et al
    Response to the Comment on "Learning Curves of Ivor Lewis Totally Minimally Invasive Esophagectomy by Hospital and Surgeon Characteristics a Retrospective Multi-national Cohort Study".
    Ann Surg. 2021;274:e930.
    PubMed    


  48. PRASAD P, Phillips AW
    Comment on "Learning Curves of Ivor Lewis Totally Minimally Invasive Esophagectomy by Hospital and Surgeon Characteristics: A Retrospective Multinational Cohort Study".
    Ann Surg. 2021;274:e929-e930.
    PubMed    


  49. HOLSCHER AH, Bollschweiler E
    Comment on "Is Local Endoscopic Resection a Viable Therapeutic Option for Early Clinical Stage T1a and T1b Esophageal Adenocarcinoma? A Propensity-matched Analysis".
    Ann Surg. 2021;274:e916-e917.
    PubMed    


  50. NABHAN FA
    Comment on "Barriers to the Use of Active Surveillance for Thyroid Cancer: Results of a Physicians Survey".
    Ann Surg. 2021;274:e880-e881.
    PubMed    


  51. SHEN H, Liu Q
    Comment on "Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors".
    Ann Surg. 2021;274:e805-e806.
    PubMed    


  52. LU J, Wu D, Huang C
    Comment on "The Relationship Between Lymph Node Ratio and Survival Benefit With Adjuvant Chemotherapy in Node-positive Esophageal Adenocarcinoma".
    Ann Surg. 2021;274:e845-e846.
    PubMed    


  53. RAJA S, Blackstone EH
    Response to the Comments on "Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma".
    Ann Surg. 2021;274:e757-e758.
    PubMed    


  54. KUROKAWA Y, Doki Y, Takeuchi H, Kitagawa Y, et al
    Response to the Comment on: Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors.
    Ann Surg. 2021;274:e806-e807.
    PubMed    


  55. FRANSEN LFC, Luyer MDP
    Response to the Comment on "The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study".
    Ann Surg. 2021;274:e741-e742.
    PubMed    


  56. ZHANG G, Zhang H, Li Q, Li J, et al
    Comment on "The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study".
    Ann Surg. 2021;274:e740-e741.
    PubMed    


  57. KHAW RA, Kamarajah SK, Phillips AW
    Comments on "Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma".
    Ann Surg. 2021;274:e756-e757.
    PubMed    


  58. MORIS D, Tsilimigras DI, Schizas D
    Comment on "The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study".
    Ann Surg. 2021;274:e744-e745.
    PubMed    


  59. FRANSEN LFC, Luyer MDP
    Response to the Comment on "The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study".
    Ann Surg. 2021;274:e745-e746.
    PubMed    


  60. KUROKAWA Y, Takeuchi H, Doki Y, Kitagawa Y, et al
    Response to the Comment on "Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors".
    Ann Surg. 2021;274:e682-e683.
    PubMed    


  61. ZHAO B, Liang R, Li G
    Comment on "Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors".
    Ann Surg. 2021;274:e681-e682.
    PubMed    


  62. VAN DER WILK BJ, van Lanschot JJB
    Response to the Comment on "Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer".
    Ann Surg. 2021;274:e697-e698.
    PubMed    


  63. GUTSCHOW CA
    Response to the Comment on "Anastomotic Techniques and Associated Morbidity in Total Minimally Invasive Transthoracic Esophagectomy: Results From the EsoBenchmark Database".
    Ann Surg. 2021;274:e686.
    PubMed    


  64. MOLENA D, Louie BE, Demeester SR
    Comment on "Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer".
    Ann Surg. 2021;274:e695-e696.
    PubMed    


  65. KAMARAJAH SK, Griffiths EA
    Comment on "Anastomotic Techniques and Associated Morbidity in Total Minimally Invasive Transthoracic Esophagectomy: Results From the EsoBenchmark Database".
    Ann Surg. 2021;274:e685-e686.
    PubMed    


  66. YONEKURA H, Nakamori Y, Takeda C, Kawasaki Y, et al
    Comment on "The Effect of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Esophageal Cancer".
    Ann Surg. 2021;274:e672.
    PubMed    


  67. FRANSEN LFC, Berkelmans GHK, Asti E, Henegouwen MIVB, et al
    The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study.
    Ann Surg. 2021;274:e1129-e1137.
    PubMed     Abstract available


  68. SAKAMOTO T, Fujiogi M, Yasunaga H
    Response to the Comment on "Effect of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Esophageal Cancer".
    Ann Surg. 2021;274:e672-e673.
    PubMed    


  69. LENG X, He W, Yang H, Chen Y, et al
    Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Ann Surg. 2021;274:e1022-e1029.
    PubMed     Abstract available


  70. MARET-OUDA J, Santoni G, Wahlin K, Artama M, et al
    Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries.
    Ann Surg. 2021;274:e535-e540.
    PubMed     Abstract available


  71. SCHOPPMANN SF, Jomrich G
    Response to the Comment on "High Systemic Immune-inflammation Index Is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma".
    Ann Surg. 2021;274:e669-e670.
    PubMed    


  72. SUN L, Liang H, Feng Y
    Comment on "High Systemic Immune-inflammation Index Is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma".
    Ann Surg. 2021;274:e668-e669.
    PubMed    


  73. VAN DER WILK BJ, Noordman BJ, Neijenhuis LKA, Nieboer D, et al
    Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study.
    Ann Surg. 2021;274:1009-1016.
    PubMed     Abstract available


    November 2021
  74. HIRANO Y, Kaneko H, Konishi T, Itoh H, et al
    Impact of Body Mass Index on Major Complications, Multiple Complications, In-hospital Mortality, and Failure to Rescue Following Esophagectomy for Esophageal Cancer: A Nationwide Inpatient Database Study in Japan.
    Ann Surg. 2021 Nov 23. pii: 00000658-900000000-93169.
    PubMed     Abstract available


  75. LIU F, Yang W, Yang W, Xu R, et al
    Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer from a Real-World Multicenter Study.
    Ann Surg. 2021 Nov 11. pii: 00000658-900000000-93196.
    PubMed     Abstract available


  76. HE Z, Liu F, Yang W, Ke Y, et al
    Response to: Comment on "Is adjuvant therapy a better option for esophageal squamous cell carcinoma patients treated with esophagectomy? A prognosis prediction model based on multicenter real-world data".
    Ann Surg. 2021 Nov 9. pii: 00000658-900000000-93201.
    PubMed    


  77. HUANG S, Wang S, Gao Z, Qiao G, et al
    Comment on "Is adjuvant therapy a better option for esophageal squamous cell carcinoma patients treated with esophagectomy? A prognosis prediction model based on multicenter real-world data".
    Ann Surg. 2021 Nov 9. pii: 00000658-900000000-93198.
    PubMed    


  78. KALFF MC, Gottlieb-Vedi E, Verhoeven RHA, van Laarhoven HWM, et al
    Presentation, Treatment, and Prognosis of Esophageal Carcinoma in a Nationwide Comparison of Sweden and the Netherlands.
    Ann Surg. 2021;274:743-750.
    PubMed     Abstract available


  79. HERTAULT H, Gandon A, Behal H, Legault G, et al
    Incidence and Risk Factors for Diaphragmatic Herniation Following Esophagectomy for Cancer.
    Ann Surg. 2021;274:758-765.
    PubMed     Abstract available


  80. MULLER PC, Morell B, Vetter D, Raptis DA, et al
    Preemptive Endoluminal Vacuum Therapy to Reduce Morbidity After Minimally Invasive Ivor Lewis Esophagectomy: Including a Novel Grading System for Postoperative Endoscopic Assessment of GI-Anastomoses.
    Ann Surg. 2021;274:751-757.
    PubMed     Abstract available


  81. DONLON NE, Kammili A, Roopnarinesingh R, Davern M, et al
    FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma.
    Ann Surg. 2021;274:814-820.
    PubMed     Abstract available


  82. WONG IYH, Zhang RQ, Tsang RKY, Kwok JYY, et al
    Improving Outcome of Superior Mediastinal Lymph Node Dissection During Esophagectomy: A Novel Approach Combining Continuous and Intermittent Recurrent Laryngeal Nerve Monitoring.
    Ann Surg. 2021;274:736-742.
    PubMed     Abstract available


    October 2021
  83. RAJA S, Rice TW, Murthy SC, Ahmad U, et al
    Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma.
    Ann Surg. 2021;274:e320-e327.
    PubMed     Abstract available


    September 2021
  84. LEE Y, Samarasinghe Y, Lee MH, Thiru L, et al
    Role of Adjuvant Therapy in Esophageal Cancer Patients after Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-Analysis.
    Ann Surg. 2021 Sep 29. pii: 00000658-900000000-93257.
    PubMed     Abstract available


  85. KLOFT M, Ruisch JE, Raghuram G, Emmerson J, et al
    Prognostic Significance of Negative Lymph Node Long Axis in Esophageal Cancer: Results From the Randomized Controlled UK MRC OE02 Trial.
    Ann Surg. 2021 Sep 13. pii: 00000658-900000000-93281.
    PubMed     Abstract available


  86. VOETEN DM, Gisbertz SS, Ruurda JP, Wilschut JA, et al
    Overall Volume Trends in Esophageal Cancer Surgery Results From the Dutch Upper Gastrointestinal Cancer Audit.
    Ann Surg. 2021;274:449-458.
    PubMed     Abstract available


  87. KAMEL MK, Harrison S, Lee B, Port JL, et al
    Extended Lymphadenectomy Improves Survival After Induction Chemoradiation for Esophageal Cancer: A Propensity Matched Analysis of the National Cancer Database.
    Ann Surg. 2021 Sep 1. pii: 00000658-900000000-93285.
    PubMed     Abstract available


  88. LIMBERG J, Ullmann TM, Stefanova D, Buicko JL, et al
    Does Aggressive Variant Histology Without Invasive Features Predict Overall Survival in Papillary Thyroid Cancer?: A National Cancer Database Analysis.
    Ann Surg. 2021;274:e276-e281.
    PubMed     Abstract available


  89. CLARK JM, Cooke DT, Hashimi H, Chin D, et al
    Do the 2018 Leapfrog Group Minimal Hospital and Surgeon Volume Thresholds for Esophagectomy Favor Specific Patient Demographics?
    Ann Surg. 2021;274:e220-e229.
    PubMed     Abstract available


    August 2021
  90. FRANSEN LFC, Luyer MDP
    Response to the Comment on "Direct Oral Feeding After Minimally Invasive Esophagectomy (NUTRIENT II trial) an International, Multicenter, Open-label Randomized Controlled Trial".
    Ann Surg. 2021;274:e196-e197.
    PubMed    


  91. MORIS D, Cerullo M
    Comment on "Direct Oral Feeding After Minimally Invasive Esophagectomy (NUTRIENT II trial): An International, Multicenter, Open-label Randomized Controlled Trial".
    Ann Surg. 2021;274:e196.
    PubMed    


  92. SAKAMOTO T, Fujiogi M, Matsui H, Fushimi K, et al
    Comparing Perioperative Mortality and Morbidity of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Retrospective Analysis.
    Ann Surg. 2021;274:324-330.
    PubMed     Abstract available


    July 2021
  93. NOMA T, Makino T, Ohshima K, Sugimura K, et al
    Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer.
    Ann Surg. 2021 Jul 29. pii: 00000658-900000000-93382.
    PubMed     Abstract available


  94. DEFIZE IL, Goense L, Borggreve AS, Mook S, et al
    Risk Factors for Tumor Positive Resection Margins After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Results from the Dutch Upper GI Cancer Audit: A Nationwide Population-Based Study.
    Ann Surg. 2021 Jul 29. pii: 00000658-900000000-93365.
    PubMed     Abstract available


  95. VOETEN DM, Busweiler LAD, van der Werf LR, Wijnhoven BPL, et al
    Outcomes of Esophagogastric Cancer Surgery during eight Years of Surgical Auditing by the Dutch Upper Gastrointestinal Cancer Audit (DUCA).
    Ann Surg. 2021 Jul 29. pii: 00000658-900000000-93364.
    PubMed     Abstract available


  96. DEMEESTER SR
    Response to the Comment on "The Prevalence of Lymph Node Metastases in Patients With T1 Esophageal Adenocarcinoma A Retrospective Review of Esophagectomy Specimens".
    Ann Surg. 2021;274:e106-e107.
    PubMed    


  97. KUROKAWA Y, Takeuchi H, Doki Y, Mine S, et al
    Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study.
    Ann Surg. 2021;274:120-127.
    PubMed     Abstract available


    June 2021
  98. GOTTLIEB-VEDI E, Kauppila JH, Mattsson F, Hedberg J, et al
    Extent of Lymphadenectomy and Long-Term Survival in Esophageal Cancer.
    Ann Surg. 2021 Jun 25. pii: 00000658-900000000-93462.
    PubMed     Abstract available


  99. YANG Y, Li B, Yi J, Hua R, et al
    Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial.
    Ann Surg. 2021 Jun 18. pii: 00000658-900000000-93478.
    PubMed     Abstract available


  100. WANG BY, Lin CH, Wu SC, Chen HS, et al
    Survival Comparison Between Open and Thoracoscopic Upfront Esophagectomy in Patients with Esophageal Squamous Cell Carcinoma.
    Ann Surg. 2021 Jun 10. pii: 00000658-900000000-93505.
    PubMed     Abstract available


  101. YANG W, Liu F, Xu R, Yang W, et al
    Is adjuvant therapy a better option for esophageal squamous cell carcinoma patients treated with esophagectomy? A prognosis prediction model based on multicenter real-world data.
    Ann Surg. 2021 Jun 2. pii: 00000658-900000000-93529.
    PubMed     Abstract available


  102. KELLY RJ, Ansari AM, Miyashita T, Zahurak M, et al
    Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma.
    Ann Surg. 2021;273:e206-e213.
    PubMed     Abstract available


    May 2021
  103. DU J, Shen X
    Comment on "Genomic Alteration and Immunity-Implications In Esophageal Cancer".
    Ann Surg. 2021 May 24. pii: 00000658-900000000-93540.
    PubMed    


  104. DU J, Guan W, Shen X
    Comment on "Circulating Tumor Cells-New Indicator For Clinical Staging Of Patients With Esophageal Cancer".
    Ann Surg. 2021 May 24. pii: 00000658-900000000-93536.
    PubMed    


  105. KOSUMI K, Baba Y, Baba H
    Response to Comment on "Genomic Alteration and Immunity-Implications in Esophageal Cancer".
    Ann Surg. 2021 May 19. pii: 00000658-900000000-93548.
    PubMed    


  106. REEH M
    Response to Comment on "Circulating Tumor Cells - New Indicator for Clinical Staging of Patients with Esophageal Cancer" by Wenxian Guan.
    Ann Surg. 2021 May 19. pii: 00000658-900000000-93547.
    PubMed    


  107. VAN DER WILK BJ, Eyck BM, Hofstetter WL, Ajani JA, et al
    Chemoradiotherapy followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-Analysis.
    Ann Surg. 2021 May 11. doi: 10.1097/SLA.0000000000004930.
    PubMed     Abstract available


  108. XIE SH, Santoni G, Malberg K, Lagergren P, et al
    Prediction Model of Long-term Survival After Esophageal Cancer Surgery.
    Ann Surg. 2021;273:933-939.
    PubMed     Abstract available


    April 2021
  109. HARADA K, Hwang H, Wang X, Abdelhakeem A, et al
    Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Ann Surg. 2021;273:751-757.
    PubMed     Abstract available


  110. RAFTERY NB, Murphy CF, Donohoe CL, O'Connell B, et al
    The Complexity of Defining Postoperative Pneumonia following Esophageal Cancer Surgery: A Spectrum of Lung Injury rather than a Simple Infective Complication? (ANNSURG-D21-00007).
    Ann Surg. 2021 Apr 1. doi: 10.1097/SLA.0000000000004873.
    PubMed    


  111. BABA Y, Kosumi K, Baba H
    Comments on "The Complexity of Defining Postoperative Pneumonia following Esophageal Cancer Surgery: A Spectrum of Lung Injury rather than a simple Infective complication?"
    Ann Surg. 2021 Apr 1. doi: 10.1097/SLA.0000000000004879.
    PubMed    


    March 2021
  112. LEVY J, Gupta V, Coburn NG
    Response to "Comment on Textbook Outcome and Survival in Patients with Gastric Cancer: An Analysis of the Population Registry of Esophageal and Stomach Tumours of Ontario (PRESTO)".
    Ann Surg. 2021 Mar 5. pii: 00000658-900000000-93662.
    PubMed    


  113. JAWITZ NG, Raman V, Jawitz OK, Shimpi RA, et al
    Utilization Trends and Volume-Outcomes Relationship of Endoscopic Resection for Early Stage Esophageal Cancer.
    Ann Surg. 2021 Mar 3. doi: 10.1097/SLA.0000000000004834.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: